Krijn Kristian Dijkstra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Krijn Kristian Dijkstra has a total of 298 co-authors. Here are the top co-authors by number of shared publications:
- Emile E. Voest
Oncode Institute, Utrecht, the Netherlands
30 shared publications - Charles Swanton
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK
20 shared publications - Sergio A. Quezada
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK
20 shared publications - Alastair Magness
The Francis Crick Institute, London, UK
19 shared publications - Allan Hackshaw
Cancer Research UK & UCL Cancer Trials Centre, UCL, London, UK
19 shared publications - Ayse U. Akarca
Department of Cellular Pathology, University College London Hospitals, London, UK
19 shared publications
Latest Publications
- Open Access
- 22 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
MHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation
Profiling antigens presented on MHC class I molecules on the cell surface is essential to identify candidate antigens for targeted and personalized immunotherapies. However, mass spectrometry-based immunopeptidomics has traditionally been limited by high input requirements, extensive sample manipulation, and expensive reagents. To overcome these challenges, we developed MHC1-TIP: a scalable, single-tube and cost-effective workflow to enable robust MHC-I ligandome recovery from cell lines, patient-derived organoids, and sub-milligram amounts of ex-vivo tumour fragments. Moreover, MHC1-TIP also preserves compatibility with additional omics profiling technologies and we demonstrate its capacity for quantitative and multimodal profiling of the proteome and immunopeptidome from the same sample to enable integrated analyses of protein expression and antigen presentation. Application of MHC1-TIP to primary renal cell carcinoma fragments revealed extensive intratumoral heterogeneity in antigen presentation that was poorly correlated with source protein expression. MHC1-TIP represents a broadly applicable and sensitive approach for low-input, multimodal immunopeptidomics with clinical and translational relevance.
- 22 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessMHC1-TIP enables single-tube multimodal immunopeptidome profiling and uncovers intratumoral heterogeneity in antigen presentation
Profiling antigens presented on MHC class I molecules on the cell surface is essential to identify candidate antigens for targeted and personalized immunotherapies. However, mass spectrometry-based immunopeptidomics has traditionally been limited by high input requirements, extensive sample manipulation, and expensive reagents. To overcome these challenges, we developed MHC1-TIP: a scalable, single-tube and cost-effective workflow to enable robust MHC-I ligandome recovery from cell lines, patient-derived organoids, and sub-milligram amounts of ex-vivo tumour fragments. Moreover, MHC1-TIP also preserves compatibility with additional omics profiling technologies and we demonstrate its capacity for quantitative and multimodal profiling of the proteome and immunopeptidome from the same sample to enable integrated analyses of protein expression and antigen presentation. Application of MHC1-TIP to primary renal cell carcinoma fragments revealed extensive intratumoral heterogeneity in antigen presentation that was poorly correlated with source protein expression. MHC1-TIP represents a broadly applicable and sensitive approach for low-input, multimodal immunopeptidomics with clinical and translational relevance.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Type of antibiotics (ATB) administered to patients in the MMR-d/MSI-H cohort.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Type of antibiotics (ATB) administered to patients in the MMR-d/MSI-H cohort.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
5-OP-RU induces MAIT cell-mediated suppression of CD4+ T cell stimulation.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
5-OP-RU induces MAIT cell-mediated suppression of CD4+ T cell stimulation.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Information on patient-derived (tumor) organoid lines.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Information on patient-derived (tumor) organoid lines.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
HMBPP-producing bacteria induce Vδ2 T cell-mediated anti-tumor activity.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
HMBPP-producing bacteria induce Vδ2 T cell-mediated anti-tumor activity.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Metagenomics data distribution in the MMR-d/MSI-H cohort.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Metagenomics data distribution in the MMR-d/MSI-H cohort.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Clinical characteristics of the Microbe-ICB cohort.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Clinical characteristics of the Microbe-ICB cohort.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Functional dysbiosis correlates with ICB response in the MMR-d/MSI-H cohort.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy
Functional dysbiosis correlates with ICB response in the MMR-d/MSI-H cohort.